Skip to main content
RENERVE LIMITED logo

RENERVE LIMITED — Investor Relations & Filings

Ticker · RNV ISIN · AU0000358616 ASX Manufacturing
Open in API
Filings indexed 134 across all filing types
Latest filing 2026-05-07 Investor Presentation
Country AU Australia
Listing ASX RNV

About RENERVE LIMITED

https://renerve.com.au/

Renerve Limited is a medical technology company focused on the development and commercialization of advanced solutions for tissue repair and regeneration. The company specializes in peripheral nerve repair through its proprietary NervAlign platform. This technology utilizes a specialized decellularization process to create high-quality nerve grafts derived from porcine tissue. These grafts are designed to provide a natural scaffold that supports and guides axonal regrowth across nerve gaps, offering an alternative to traditional autografts. By maintaining the structural integrity and biochemical cues of the extracellular matrix, Renerve's products aim to improve functional recovery outcomes for patients suffering from traumatic nerve injuries. The company's research and development efforts are centered on expanding the applications of its tissue engineering platform to address various clinical needs in regenerative medicine.

Recent filings

Filing Released Lang Actions
Quarterly Investor Presentation 21 pages 2.1MB
Investor Presentation Classification · 95% confidence The document is a detailed company presentation from ReNerve Ltd dated May 2026. It includes extensive information about the company's products, market strategy, sales and marketing updates, clinical studies, regulatory milestones, and product development pipeline. The content is structured as a presentation with slides, charts, and images, focusing on business strategy, product portfolio, market expansion, and clinical validation. There is no indication that this is a transcript of a call, an earnings release, or a regulatory filing. It is not an annual or quarterly report containing financial statements or detailed financial analysis. The document is clearly a presentation aimed at investors or stakeholders, providing an overview of the company's operations, strategy, and market position. Therefore, the most appropriate classification is Investor Presentation (IP).
2026-05-07 English
Notification of cessation of securities - RNV 7 pages 21.3KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the cancellation of various options and securities by agreement between the entity and holders. It includes specific ASX security codes, descriptions, numbers of securities ceased, reasons for cessation, and dates. The document is a formal announcement to the ASX about changes in the company's issued capital due to cessation of securities, including forfeiture due to cessation of employment. There are no financial statements, management discussion, or earnings data. The content is focused on changes in securities issued and ceased, which aligns with announcements about share or capital changes. Therefore, the document fits the category of Share Issue/Capital Change (SHA).
2026-04-30 English
Quarterly Investor Webinar 3 pages 395.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 1 May 2026 inviting shareholders and investors to a webinar discussing the March 2026 quarterly report and further company updates. It does not contain the actual quarterly financial report or substantive financial data but rather announces an event to discuss the report. The document length is 4754 characters, which is relatively short and consistent with an announcement rather than a full report. There is no detailed financial data or analysis present. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about an upcoming event related to the quarterly report, not the report itself.
2026-04-30 English
Q3 FY26 Activities Report and Appendix 4C 11 pages 605.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled as a Quarterly Activities Report for the period ended 31 March 2026, which corresponds to a quarterly financial and operational update. It contains detailed financial data such as sales revenue, cash flows, R&D expenditure, and operating costs. It also includes corporate updates like board changes and product development progress. The presence of substantive financial data and analysis for a period shorter than a full fiscal year (quarterly) confirms it is a comprehensive interim report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2026-04-29 English
Final Director's Interest Notice - D Rhodes 2 pages 312.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director's Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the securities interests of a director, including unlisted options and ordinary shares, and notes the director's cessation date. This type of document is a report of personal share transactions or holdings by a company director, which aligns with the definition of 'Director's Dealing' filings. The document length is short and focused solely on director interests, with no financial results or other report content. Therefore, the correct classification is 'DIRS' for Director's Dealing.
2026-04-29 English
Nerve Guide Matrix Enters Stage 3 of Commercial Development 3 pages 320.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 15 April 2026 from ReNerve Limited, describing the progress of a product (Nerve Guide Matrix) entering stage 3 of commercial development and preparation for FDA submission. It includes product development updates, market information, and company growth highlights. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The document is a corporate announcement about product development and commercial progress rather than a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information rather than just announcing a report release. Therefore, the document fits best into the category of a Regulatory Filing (RNS) as a general corporate announcement that does not fit other specific categories.
2026-04-14 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.